J Cancer Metastasis Treat 2021;7:[Accepted].10.20517/2394-4722.2021.120@The Author(s) 2021
Bone marrow niches in myelodysplastic syndromes
Correspondence Address: Giovanna Tosato, Laboratory of Cellular Oncology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. E-mail: firstname.lastname@example.org; ORCID: 0003-1663-3227
Received: 18 May 2021 | Revised: 6 Jul 2021 | Accepted: 14 Jul 2021 | First online: 14 Jul 2021
AbstractGenetic and epigenetic lesions within hematopoietic cell populations drive diverse hematological malignancies. Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms affecting the hematopoietic stem cells characterized by recurrent genetic abnormalities, myelodysplasia (a pathological definition of abnormal bone marrow structure), ineffective hematopoiesis resulting in blood cytopenia, and a propensity to evolve into acute myelogenous leukemia. Although there is evidence that the accumulation of a set of genetic mutations is an essential event in MDS, there is an increased appreciation of the contribution of specific microenvironments, niches, in the pathogenesis of MDS and response to treatment. In physiologic hematopoiesis, niches are critical functional units that maintain hematopoietic stem and progenitor cells and regulate their maturation into mature blood cells. In MDS and other hematological malignancies, altered bone marrow niches can promote the survival and expansion of mutant hematopoietic clones and provide a shield from therapy. In this review, we focus on our understanding of the composition and function of hematopoietic niches and their role in the evolution of myeloid malignancies, with a focus on MDS.
KeywordsHematological malignancies, endothelial cells, stromal cells, bone marrow niches, microenvironment, angiogenesis, inflammation, hypoxia
Cite This Article
Tosato G, Feng JX, Ohnuki H, Sim M. Bone marrow niches in myelodysplastic syndromes. J Cancer Metastasis Treat 2021;7:[Accept]. http://dx.doi.org/10.20517/2394-4722.2021.120